Abstract
Previously we reported that Apolipoprotein E (ApoE) ε4 negatively affects performance in the novel-image-novel- location (NINL) object recognition test in healthy non-demented elderly human study participants. In this study, the participants were invited to return for testing sessions 6 and 18 months after the baseline session. Using a longitudinal study design, effects of ε4 on NINL test performance were assessed in study “dropouts”, participants that did not return for the second and/or third session(s), and “finishers”, participants that returned for all sessions. There were effects of ε4 on dropout rates and NINL total scores as well as sub-scores in both dropouts and finishers. NINL total score was a predictor of ε4 participant dropout. Compared to non-ε4 dropouts, ε4 dropouts had lower NINL scores. In contrast, ε4 finishers had higher NINL scores than non-ε4 finishers. Thus, the NINL test could be a valuable tool in detecting preclinical signs of age-related cognitive impairments, particularly those associated with ε4 risk.
Keywords: ApoE, object recognition, aging, cortisol, testosterone, humans
Current Aging Science
Title: Effects of ε4 on Object Recognition in the Non-Demented Elderly
Volume: 3 Issue: 2
Author(s): Gwendolen E. Haley, Frederique Berteau-Pavy, Byung Park and Jacob Raber
Affiliation:
Keywords: ApoE, object recognition, aging, cortisol, testosterone, humans
Abstract: Previously we reported that Apolipoprotein E (ApoE) ε4 negatively affects performance in the novel-image-novel- location (NINL) object recognition test in healthy non-demented elderly human study participants. In this study, the participants were invited to return for testing sessions 6 and 18 months after the baseline session. Using a longitudinal study design, effects of ε4 on NINL test performance were assessed in study “dropouts”, participants that did not return for the second and/or third session(s), and “finishers”, participants that returned for all sessions. There were effects of ε4 on dropout rates and NINL total scores as well as sub-scores in both dropouts and finishers. NINL total score was a predictor of ε4 participant dropout. Compared to non-ε4 dropouts, ε4 dropouts had lower NINL scores. In contrast, ε4 finishers had higher NINL scores than non-ε4 finishers. Thus, the NINL test could be a valuable tool in detecting preclinical signs of age-related cognitive impairments, particularly those associated with ε4 risk.
Export Options
About this article
Cite this article as:
E. Haley Gwendolen, Berteau-Pavy Frederique, Park Byung and Raber Jacob, Effects of ε4 on Object Recognition in the Non-Demented Elderly, Current Aging Science 2010; 3 (2) . https://dx.doi.org/10.2174/1874609811003020127
DOI https://dx.doi.org/10.2174/1874609811003020127 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melatonin Role in Experimental Arthritis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Current Pharmaceutical Design Atomoxetine Protects Against NMDA Receptor-mediated Hippocampal Neuronal Death Following Transient Global Cerebral Ischemia
Current Neurovascular Research Triptolide Rescues Spatial Memory Deficits and Amyloid-β Aggregation Accompanied by Inhibition of Inflammatory Responses and MAPKs Activity in APP/PS1 Transgenic Mice
Current Alzheimer Research Inhibition of Tau Aggregation in Cell Models of Tauopathy
Current Alzheimer Research Role of CNS Transporters in the Pharmacotherapy of HIV-1 Associated Neurological Disorders
Current Pharmaceutical Design Conformational Changes and Aggregation of Expanded Polyglutamine Proteins as Therapeutic Targets of the Polyglutamine Diseases: Exposed β-Sheet Hypothesis
Current Pharmaceutical Design Quantitative μPET Imaging of Cerebral Glucose Metabolism and Amyloidosis in the TASTPM Double Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Population Studies of Association Between Lithium and Risk of Neurodegenerative Disorders
Current Alzheimer Research Detection of Mild Cognitive Impairment Based on Virtual Reality: A Scoping Review
Current Alzheimer Research Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Heme Oxygenase-1 Dysregulation in the Brain: Implications for HIVAssociated Neurocognitive Disorders
Current HIV Research Imaging of Sigma1 Receptors in the Human Brain Using PET and [11C]SA4503
Central Nervous System Agents in Medicinal Chemistry Editorial [ Cardiovascular Risk Factor Modification: A sine qua non in the Management of Vascular Surgery Patients ]
Current Vascular Pharmacology Therapeutic Advancement in Alzheimer Disease: New Hopes on the Horizon?
CNS & Neurological Disorders - Drug Targets Oxidant/Antioxidant Imbalance and the Risk of Alzheimer's Disease
Current Alzheimer Research Recent Developments on the Studies of Human Memapsin 2 (β-Secretase)
Current Alzheimer Research Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson’s Disease: Defining the Preclinical, Clinical and Toxicity Issues
Current Drug Delivery Neuroimaging Studies of Substance Abuse in Schizophrenia
Current Psychiatry Reviews A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases
Current Pharmaceutical Design